{"page_content": "83\nUltragenyx 2022 ESG ReportLETTER FROM OUR CEO                     ABOUT US                     ESG GOVERNANCE & STRATEGY                     INNOVATION                      PATIENTS                      PEOPLE                      COMMUNITIES                      PLANET                      GOVERNANCE                      SASB INDEX                      GRI INDEX\nACTIVITY METRIC\nTOPIC ACCOUNTING METRICCODE\nCODERESPONSE / REFERENCE / REPORT LOCATION\nRESPONSE / REFERENCE / REPORT LOCATIONNumber of drugs 1) in portfolio and 2) in research and development (Phases 1-3)\nAccess to Medicines Description of actions and initiatives to promote access to health care\nproducts for priority diseases and in priority countries as defined by \nthe Access to Medicine Index\nList of products on the WHO List of Prequalified Medicinal Products as \npart of its Prequalification of Medicines Programme (PQP)Number of patients treated\nSafety of Clinical Trial Participants Discussion, by world region, of management process for ensuring quality \nand patient safety during clinical trials\nNumber of FDA Sponsor Inspections related to clinical trial management \nand pharmacovigilance that resulted in: (1) Voluntary Action Indicated \n(VAI) and (2) Official Action Indicated (OAI)\nTotal amount of monetary losses as a result of legal proceedings \nassociated with clinical trials in developing countriesHC-BP-000.A\nHC-BP-210a.1\nHC-BP-210a.2\nHC-BP-210a.3HC-BP-000.B\nHC-BP-240a.1\nHC-BP-240a.2>3,200. See our 2022 ESG Report, About Us.\nSee our 2022 ESG Report, Quality  and Safety . 4 drugs in portfolio; 7 drugs in development Phases 1-3. See our current Pipeline .\nWhile not listed as a company in scope for the 2022 Access to Medicine Index, we are \ncommitted to increasing access to their medicines and pricing responsibly. Our commercial \nproducts and clinical pipeline do not cover any priority countries or diseases listed in the Access \nto Medicine Index. For more information, see our 2022 ESG Report, Access & Affordability.\nUltragenyx does not have any products that qualify for the WHO List of Prequalified Medicinal \nProducts at this time.NoneNoneSASB Index\nThe following index lists the activity and accounting metrics from the Sustainability Accounting Standards Board (SASB) Biotechnology and \nPharmaceuticals Industry Standard (2018) with associated response, reference or report location.", "metadata": {"source": "NASDAQ_RARE_2022.pdf", "page": 82, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}